Field
     Antibody drug, Medicinal drug

Keywords
     Chronic Inflammation, Rheumatism, TN-C, Peptide

Advantages
     Currently IL-6- and TNFα- blocking antibodies are marketed for the treatment of chronic
     inflammation. However, when these antibody drugs are used as such, the occurrences of
     unexpected adverse effects or drug resistance, or individual differences in their effects have all
     been pointed out. Thus the development of a drug with a different action mechanism has been
     long awaited. Fukai et al. found that when Tenascin-C highly expressed in the damaged tissue is
     degraded by a simultaneously-released proteolytic enzyme, non-expressing functional site TNIIIA2
     will be released, resulting in chronic inflammation. They further discovered that the anti-TNIIIA2
     antibody that blocks the function of released TNIIIA2 could be used for treating chronic
     inflammation, and completed trialing it as a drug candidate.

     Further investigation resulted in it possibly being used as an antitumor medicine, and for treating
     hepatitis, neoplastic colitis and other diseases.
     This invention relates to a treating agent for chronic inflammation.
     This anti-TNIIIA2 antibody suppresses the infiltration of macrophage from blood vessels and also
     suppresses the survival of macrophage in the tissues whereby it is expected to treat the chronic
     inflammation.


Abstract
Provided are a remedy for chronic inflammation which comprises an antibody capable of recognizing a peptide (TNIIIA2) derived from partial sequence A2 of human Tenascin-C fibronectin III-like repeats; and the anti-TNIIIA2 antibody to be used therein.
Because an amino-acid sequence (TNIIIA2) as a cell-adhesive substrate in Tenascin exclusively plays a critical role, an antibody to its active site has been produced. The antibody has been able to be used for treating chronic inflammation by blocking the function of TNIIIA2. Then, we filed patent applications for the antibody and for its therapeutic use. After these applications, we filed additional patent applications have been made since there is the possibility of using it for other purposes.
Tenascin has been focused on and studied by many companies, the majority of which were unable to discover the most important part of its function and have given up their studies of it.

To access the rest of the information on this page,
Log In or sign up for a free B-Bridge account: